"Global Bleeding Disorders Treatment Market" By Type (Hemophilia A, Hemophilia B, (VWD), Drug Class (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealant), Geography (North America, Europe, Asia-Pacific, Europe, South America, Middle East and Africa) – Industry Trends and Forecast to 2024
- Advertising -
The new report “Global Bleeding Disorders Treatment Market” accounted to USD 12.4 billion in 2016 growing at a CAGR of 11.1% during the forecast period of 2017 to 2024. The upcoming market report contains data for historic year 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.
Bleeding disorder is a medical situation described by the despicable working of blood clotting procedure known as coagulation. Body’s coagulation framework can’t shape blood clumps at the site of damage or injury, at cuts made amid surgery, feminine cycle which results in large amounts of blood loss.
- Advertising -
Major market drivers and restraints:
- Increase of technological advancement and R&D activities
- More number of related patients
- Growing awareness among people
- Initiatives by Government
On the basis of type, the global bleeding disorders treatment market is segmented into hemophilia a, hemophilia B, and Von Willebrand Disease (VWD). In 2016, hemophilia A dominated the market with the largest market share.
On the basis of drug class, the global bleeding disorders treatment market is segmented into plasma derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, antifibrinolytics, and fibrin sealant. Here, recombinant coagulation factor concentrates led the largest market share in 2016 due to its extensive R&D investment made by the players for the production of recombinant products.
On the basis of geography, the global bleeding disorders treatment market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific, and Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others.
In 2017, North America is expected to dominate the market.
The global bleeding disorders treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes bleeding disorder treatment shares for global, Europe, North America, Asia Pacific, and South America.
Major Market Competitors:
Some of the major players operating in the global bleeding disorders treatment market are Shire (U.S.), Baxter (U.S), CSL Behring (U.S.), Alnylam Pharmaceuticals, Inc.(U.S), Bayer AG (Germany), Novo Nordisk A/S (Denmark), Pfizer Inc. (U.S.), Xenetic Biosciences, Inc. (U.S), Biogen (U.S.), Bristol-Myers Squibb Company (U.S), Octapharma (Switzerland), Sanofi (France), Amgen, Inc.(U.S), Bioverativ (U.S), Janssen Global Services, LLC (U.S), Cangene Corporation (Canada), and CSL Behring (U.S) among others.
Browse Full Report Visit @ databridgemarketresearch.com/reports/global-bleeding-disorders-treatment-market/
Category: Market Research Publishers and RetailersCompany profile: Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wi ...
For more information: